Send to

Choose Destination
Scand J Rheumatol. 2016;45(2):87-98. doi: 10.3109/03009742.2015.1060259. Epub 2015 Oct 20.

Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

Author information

a Rheumatology, Biomarkers and Research , Nordic Bioscience , Herlev , Denmark.
b Thurston Arthritis Research Center , University of North Carolina , NC , USA.
c Centre for Clinical and Basic Research , Ballerup , Denmark.
d New York University School of Medicine and Hospital for Joint Diseases, NYU Langone Medical Center , New York , NY , USA.
e Department of Rheumatology, AP-HP Saint-Antoine Hospital , Sorbonne University , Paris , France.
f Department of Medicine and Duke Molecular Physiology Institute , Duke University School of Medicine , Durham , NC , USA.


The disabling and painful disease osteoarthritis (OA) is the most common form of arthritis. Strong evidence suggests that a subpopulation of OA patients has a form of OA driven by inflammation. Consequently, understanding when inflammation is the driver of disease progression and which OA patients might benefit from anti-inflammatory treatment is a topic of intense research in the OA field. We have reviewed the current literature on OA, with an emphasis on inflammation in OA, biochemical markers of structural damage, and anti-inflammatory treatments for OA. The literature suggests that the OA patient population is diverse, consisting of several subpopulations, including one associated with inflammation. This inflammatory subpopulation may be identified by a combination of novel serological inflammatory biomarkers. Preliminary evidence from small clinical studies suggests that this subpopulation may benefit from anti-inflammatory treatment currently reserved for other inflammatory arthritides.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center